Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001097 · ClinicalTrials.gov registry record
Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems
A clinical trial of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 120
- Enrollment target
- 20
- Study locations
NCT00001097 is a study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 120 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT00001097, a study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if children and young adults with better immune systems before starting highly active antiretroviral therapy (HAART) do better than those who have weaker immune systems before starting HAART. HIV infection weakens the immune system's ability to fight other infections and diseases. HAART is a type of anti-HIV therapy shown to improve the immune system of adults. However, not all patients show the same amount of improvement with HAART. Doctors believe that results may depend on how strong a patient's immune system is before starting HAART. Long-term effects of HAART in children and young adults have not yet been studied.
Conditions Studied
Study Locations (20)
Florida
- North Broward Hosp District - Fort Lauderdale
- Univ of Florida Gainesville - Gainesville
- Univ of Florida Health Science Ctr / Pediatrics - Jacksonville
- Univ of Miami (Pediatric) - Miami
- Palm Beach County Health Dept - Riviera Beach
California
- UCSD Med Ctr / Pediatrics / Clinical Sciences - La Jolla
- Children's Hosp of Los Angeles/UCLA Med Ctr - Los Angeles
- Los Angeles County - USC Med Ctr - Los Angeles
- Harbor - UCLA Med Ctr / UCLA School of Medicine - Los Angeles
Illinois
- Cook County Hosp - Chicago
- Univ of Illinois College of Medicine / Pediatrics - Chicago
- Chicago Children's Memorial Hosp - Chicago
- Univ of Chicago Children's Hosp - Chicago
Alabama
- Univ of Alabama at Birmingham - Pediatric - Birmingham
- Univ of South Alabama - Mobile
Arizona
- Phoenix Childrens Hosp - Phoenix
Colorado
- Children's Hosp of Denver - Denver
Connecticut
- Connecticut Children's Med Ctr - Farmington
District of Columbia
- Howard Univ Hosp - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1997-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001097
The ClinicalTrials.gov registry entry for NCT00001097 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (73% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.
NCT00001097 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00001097 about?
NCT00001097 is a clinical study titled "Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems". The purpose of this study is to see if children and young adults with better immune systems before starting highly active antiretroviral therapy (HAART) do better than those who have weaker immune systems before starting HAART. HIV infection weakens the immune system's ability to fight other infect...
What is the current status of trial NCT00001097?
This trial is currently completed. The enrollment target is 120 participants. The study started on 1997-12.
What conditions does trial NCT00001097 study?
This clinical trial studies the following conditions: HIV Infections.
Who is sponsoring clinical trial NCT00001097?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001097 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.